Dr. Michael Blaiss MD
Partner, ALLERGY & ASTHMA CARE
Member of the Healthcare Council
Council Member Biography
Michael S. Blaiss, MD, is an Allergist and Clinical Professor of Pediatrics and Medicine at the University of Tennessee Health Sciences Center in Memphis and has a private practice in Memphis at Allergy and Asthma Care. Dr. Blaiss has been named to the list “Best Doctors in America” from 1999-2010. In 2009, he was named by USA Today as one of the most influential physicians in asthma care. He has been a member of the editorial boards for the Annals of Allergy, Asthma, and Immunology, World Allergy Organization Journal, Journal of Asthma, and Allergy and Asthma Proceedings, and American Journal of Rhinology and Allergy. Dr. Blaiss is presently Contributing Editor for the Asthma Resource Center for Epocrates.com. He is presently on the Board of Directors of the World Allergy Organization. Dr. Blaiss is the Past President of the American College of Allergy, Asthma, and Immunology and has served on the Board of Directors for the American Board of Allergy and Clinical Immunology. He has been President of the Tennessee and Louisiana Allergy, Asthma, and Immunology Societies. Dr. Blaiss is a Fellow of the American College of Allergy, Asthma, and Immunology and the American Academy of Allergy, Asthma, and Immunology. (This is me - Update Profile)
Employment History
- 2000 - Unspecified
- Clinical Professor of Pediatricsand Medicine, UNIVERSITY OF TENNESSEE
- 2000 - Unspecified
- Partner, ALLERGY & ASTHMA CARE
GLG NewsSM Analyses by Michael Blaiss
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
It's Hot: A New Treatment for Asthma
April 26, 2006
Bronchial Thermoplasty for Asthma | ajrccm.atsjournals.org
Bronchial thermoplasty (BT) reduces the potential for smooth muscle–mediated bronchoconstriction by reducing the mass of smooth muscle in the walls of conducting airways.
This study showed clinical improvement over 12 weeks in a small group of mild to moderate asthma patients. Also the authors showed improvement in bronchial hyperreactivity over 2 years which suggests continued clinical improvement or stability of the patient's asthma. No significant side effects were seen.
Asthmatx is the developer of this technique. A major study is on going for FDA approval which the company states should be published in 2008 . It is probably worth looking at as a future player in asthma care. -
April 17, 2006
The Effect of Telithromycin in Acute Exacerbations of Asthma | content.nejm.org
This study assessed adults with an acute exacerbation of their asthma to determine if 10 days of oral treatment with telithromycin (Ketek) (at a dose of 800 mg daily) in addition to usual care lead to faster and more efficacious relief of their asthma. This double blind trial showed improvement on one primary efficacy end point: change from baseline over the treatment period in symptoms (as recorded by patients in a diary card) but not in the peak expiratory flow in the morning at home. Although 61 percent of patients had evidence of infection with C. pneumoniae, M. pneumoniae, or both, there was no relationship between bacteriologic status and the response to asthma treatment.
-
Do Long-Acting Beta Agonists Kill Asthma Patients?
April 7, 2006
Trouble Breathing | www.forbes.com
This article published in Forbes and the interview on the Today Show on 4/6/06 discussed the possible adverse reactions and death associated with the use of salmeterol, a long-acting beta agonist for asthma, used alone and in combination with fluticasone, an inhaled corticosteroid, under the trade name of Advair in the United States. With the new stricter indication and black box warning with salmeterol by the FDA this year and the recent press about the possibility of increased risk of death in asthma patients using this agent, there will probably be a decrease of use of this agent as a first-line medication in asthma especially in the primary care arena.
-
April 6, 2006
Evidence of a role of tumor necrosis factor alpha in refractory asthma | content.nejm.org
Severe refractory asthmatics are the highest cost asthma patients for managed care due to increased emergency department visits and hospitalizations. This preliminary study suggests that soluble TNF--
<!--[endif]--> receptor etanercept (25 mg twice weekly) in the patients with refractory asthma leads to improve in several aspects of asthma control. Therefore this agent may have a role in management of severe asthma.
GLG Study Groups with Michael Blaiss(?)
| Study Group Name | No. Members |
|---|---|
| Pediatricians (US) | 1717 |
| Pulmonologists (US) | 771 |
| Physicians who Treat Asthma (US) | 679 |
| Physicians in the U.S. who Treat Chronic Obstructive Pulmonary Disease (COPD) | 447 |
| Allergists (US) | 416 |
GLG Live Meetings with Michael Blaiss(?)
Michael Blaiss has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.